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Abstract
Interstitial lung disease (ILD) is a complex and heterogeneous disorder that is often associated
with autoimmune syndromes (1). Despite the connection between ILD and autoimmunity, it
remains unclear whether ILD can develop from an autoimmune response that specifically targets
the lung parenchyma. Here, we utilized a severe form of autoimmune disease, Autoimmune
Polyglandular Syndrome Type 1 (APS1), to establish a strong link between an autoimmune
response to the lung-specific protein BPIFB1 and clinical ILD. Screening of a large cohort of
APS1 patients revealed autoantibodies to BPIFB1 in 9.6% of APS1 subjects overall and in 100%
of APS1 subjects with ILD. Further investigation of ILD outside the APS1 disorder revealed
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BPIFB1 autoantibodies specifically present in 14.6% of patients with connective tissue disease-
associated ILD and in 12.0% of patients with idiopathic ILD. Utilizing the animal model for APS1
to examine the mechanism of ILD pathogenesis, we found that Aire−/− mice harbor autoantibodies
to a similar lung antigen named BPIFB9 that are a marker for ILD, and determined that a defect in
thymic tolerance is responsible for the production of BPIFB9 autoantibodies and the development
of ILD. Importantly, we also found that immunoreactivity targeting BPIFB1 independent of a
defect in Aire also leads to ILD, consistent with our discovery of BPIFB1 autoantibodies in non-
APS1 patients. Overall, our results demonstrate that autoimmunity targeting the lung-specific
antigen BPIFB1 may be important to the pathogenesis of ILD in patients with APS1 and in subsets
of patients with non-APS1 ILD, demonstrating the role of lung-specific autoimmunity in the
genesis of ILD.
Introduction
Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders
characterized by chronic inflammation and fibrosis within the connective tissue of the lung.
The onset of ILD has been correlated with many exposures and well-characterized diseases
but the primary mechanisms that trigger ILD remain elusive. Increasing evidence suggests a
potential role of autoimmunity in ILD pathogenesis (2–4). ILD can develop in nearly all
autoimmune connective tissue diseases, including common disorders like rheumatoid
arthritis (1, 4). Due to the lack of specific markers to diagnose lung autoimmunity, it
remains unclear whether patients with idiopathic ILD may have a component of lung
autoimmunity, as select patients with idiopathic ILD also share identical histopathology to
ILD patients with defined autoimmune syndromes (2, 3, 5, 6). Prior studies have not
identified an autoantigen clearly involved in the pathophysiology of ILD, and none of the
putative antigens associated with ILD show lung-specific expression, raising the question
whether such autoantibodies arise as secondary phenomena or through epitope spreading (7–
9). Thus, despite evidence implicating autoimmunity in ILD, studies have yet to identify a
pathogenic mechanism whereby an autoimmune response specifically targets the lung within
ILD patients.
Insights from rare extremes of disease can be applied to understand more common disorders;
for example, the discovery of the type 1 diabetes-associated autoantigen GAD65 arose from
studying patients with a rare, severe autoimmune disease termed Stiff Person Syndrome
(10). We hypothesized that this approach could be used to identify lung autoantigens in ILD
by studying subjects with the rare monogenic disorder, Autoimmune Polyglandular
Syndrome Type 1 (APS1). APS1 patients develop multiple organ-specific autoimmune
diseases that are associated with autoantibodies to established organ-specific antigens (11,
12). Recently, ILD has been recognized as an important manifestation of APS1 and is
characterized by prominent bronchiolar inflammation (13, 14), similar to ILD commonly
seen in systemic autoimmune disorders (1, 15). Importantly, APS1 arises from defects in the
Autoimmune regulator (AIRE) gene, a key modulator of central immune tolerance with a
known mechanism and well-defined animal model (16). Thus, this model represents an
attractive system of organ-specific autoimmunity to examine lung-specific autoimmunity in
ILD.
Results
Autoantibodies to the BPIFB1 lung antigen in APS1 patients with ILD
We first noted autoantibodies to BPIFB1 (bactericidal/permeability-increasing fold-
containing B1) protein in an APS1 patient with ILD (14). To determine if BPIFB1
autoantibodies are broadly specific for ILD in subjects with APS1, we tested a large APS1
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cohort for BPIFB1 autoantibodies using a radioligand-binding assay (RLBA). A limited
number of APS1 subjects or controls had values near the assay cut-off consistent with non-
specific binding but 10/104 (9.6%) APS1 subjects had markedly elevated serum
autoantibodies against BPIFB1 (Fig. 1). Review of the available clinical data revealed 6
APS1 patients with clinically significant pulmonary disease verified in pulmonary function
tests (PFT) or chest radiographs (Table 1). Remarkably, 100% of APS1 patients with ILD
had high BPIFB1 autoantibody titers, and all available biopsies revealed ILD characterized
by bronchiolar inflammation in these patients (5/6). None of the other APS1 patients tested
had abnormal PFTs or chest radiographs at the time of serum sampling. Based on these
results, the sensitivity and specificity of our assay, using an ROC cutoff value of 16, were
100% (CI 54.07–100%) and 94.9% (88.49–98.32%), respectively (Fig. S1) and the area
under the curve (AUC) in the receiver operating characteristics analysis was 0.987 (95% CI
0.966 to 1.01; P<0.0001). These data suggest that the BPIFB1 autoantibody assay is a highly
sensitive and specific test for detecting pulmonary disease that has been confirmed in PFTs
or chest radiographs.
Having shown that BPIFB1 autoantibodies are highly sensitive and specific for ILD in
APS1, we next asked whether BPIFB1 exhibits a tissue restricted expression pattern similar
to other antigens in the Aire model. We investigated the human tissue expression of BPIFB1
by quantitative real-time PCR. High levels of BPIFB1 transcripts were limited to the lung
and low levels were found in multiple organs including the thymus, the location outside of
the lung with the highest tissue expression (Fig. S2). Importantly, this pattern of both tissue-
specific and thymic expression mirrors other organ-specific antigens identified in the Aire-
deficient model that have critical roles in the pathogenesis of organ autoimmunity (14, 17–
20). Taken together, our results demonstrate that BPIFB1 is a lung-specific autoantigen in
APS1 patients with interstitial lung disease.
Autoantibodies to BPIFB1 in ILD patients without APS1
We next hypothesized that that the BPIFB1 antigen may be targeted in a subset of ILD
patients outside of the APS1 disorder, especially in the setting of systemic autoimmunity.
Screening of a heterogeneous cohort of patients with connective tissue disease-associated
ILD (Fig. S3) revealed that 14.6%, (7/48) had elevated BPIFB1 autoantibodies (Fig. 2,
Table S1). Given that subclinical or occult lung-restricted autoimmunity could play a role in
patients without other known etiologies for ILD, we extended screening to a large,
heterogeneous cohort of subjects with idiopathic ILD (Fig. S4). We found that 12.0%
(13/108) of such patients harbored BPIFB1 autoantibodies (Fig. 2, Table S2), whereas no
BPIFB1 autoantibodies were detected in non-ILD lung disease controls matched for age and
race to all of the non-APS1 BPIFB1-positive subjects (Fig. 2, Fig. S5). Having identified a
subset of idiopathic and connective tissue disease-associated ILD (CTD-ILD) patients that
were positive in the BPIFB1 assay, we next tested them specifically for autoantibodies to
IFNř. The IFNř autoantibody assay is a highly sensitive and specific test to diagnose APS1
(Fig. S6B), including cases of undetected or subclinical disease (21–23). We determined that
100% of APS1 patients had circulating IFNř autoantibodies, whereas none of the CTD-ILD
or idiopathic ILD patients had a positive IFNř titer, confirming that these subjects did not
have APS1 disease (Fig. S6A). Finally, in order to verify that BPIFB1 autoantibodies are not
broadly associated with autoimmune disorders or autoimmune inflammation, we tested
subjects with type 1 diabetes, a disease characterized by multiple circulating autoantibodies
without lung pathology, and found that none of these patients were positive in the assay (Fig
2). Taken together, these results suggest that BPIFB1 autoantibodies are a specific marker
for lung autoimmunity.
Shum et al. Page 3
Sci Transl Med. Author manuscript; available in PMC 2014 April 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Validation of the BPIFB1 radioligand binding assay
To characterize the tissue specificity of serum BPIFB1 autoantibodies, we performed
indirect immunofluorescence staining of fresh frozen lung sections (Fig. 3A). Staining with
a commercial BPIFB1 antibody revealed reactivity to the bronchiolar epithelium. Strikingly
similar staining was seen using the serum from either an APS1 ILD patient or a non-APS1
ILD patient with BPIFB1 autoantibodies. To validate this result, we performed a
competition reaction in which the serum used for staining was pre-absorbed with
commercial unlabeled recombinant BPIFB1 and then tested in the RLBA. We could
successfully compete out specific binding of BPIFB1 serum autoantibodies using the
unlabeled recombinant BPIFB1 protein (Fig. 3B). Finally, to further confirm that the
autoantibody response in our RLBA was specific for the BPIFB1 protein, we also performed
a sequential immunoprecipitation with radiolabeled BPIFB1. Initial immunoprecipitations
were performed using serum samples with and without BPIFB1 autoantibodies. The second
and final immunoprecipitation was performed with a commercial anti-human BPIFB1
antibody to capture any remaining antigen. Only samples from patients positive for BPIFB1
autoantibodies on RLBA were able to deplete out the radiolabeled BPIFB1 protein (Fig.
3C). The identification of BPIFB1 autoantibodies in ILD subjects suggests that the
bronchiolar epithelium may be a critical target for autoimmune lung reactions and provides
further evidence that terminal bronchioles may be an important site in the pathogenesis of
ILD and pulmonary fibrosis (24).
Autoantibodies to BPIFB9 as a marker for ILD in Aire-deficient mice
Autoantibodies frequently arise from recognition of cognate antigens with corresponding T-
cell specificity. As such, they can directly mediate pathogenic effects in some diseases (25)
or arise secondary to a T cell driven response (26). The contribution of antigen-specific B
and T cell immunity can be difficult to assess in human subjects (27). Thus, to better
examine the autoimmune mechanism of ILD induction, we turned to the Aire−/− mouse
model of APS1, which manifests multi-organ autoimmunity and lung disease as in APS1
patients (14). Significantly, we recently identified the lung self-antigen BPIFB9, a murine
BPIFB family protein with high similarity to BPIFB1, in Aire−/− mice with lung
autoimmunity (14). First, to establish if BPIFB9 autoantibodies in our mouse model also act
as a marker for ILD, as demonstrated in our human cohorts, we assessed Aire−/− animals by
both RLBA and lung histology scores (Fig. 4A). Nearly all Aire−/− mice with histologic
lung disease (24/27, 89%) had BPIFB9 autoantibodies while no autoantibodies were
detected in wild-type controls. Moreover, the mean autoantibody index of mice with severe
disease (score=3 mean index=95.03) was significantly elevated over Aire−/− mice without
histologic disease (score=0, mean index=10.5, P=0.0002) or mild disease (score=1, mean
index=48.3, P=0.0185). Given that BPIFB9 autoantibody titers appear to directly correlate
with disease severity, we next sought to evaluate whether BPIFB9-specific autoantibodies
are sufficient to cause disease. We generated serum with elevated BPIFB9 autoantibodies by
immunizing Aire−/− mice with the BPIFB9 protein. We confirmed that the serum isolated
from these mice contained markedly elevated BPIFB9 autoantibodies (Fig. S7A) and then
intravenously injected 50uL of this serum or wild-type control serum every other day into 2
separate cohorts of wild-type mice over a period of 10 days. One week after the final serum
transfer all of the mice were sacrificed and analyzed for disease. None of the mice in either
group developed lung disease (Fig. S7B). Thus, while the BPIFB9 autoantibody index
correlates with disease severity and may serve as a marker of murine ILD, BPIFB9
autoantibodies do not appear to be sufficient for induction of ILD.
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Induction of ILD by BPIFB9-specific CD4+ T cells
Given the important role CD4+ T cells play in orchestrating autoimmune diseases and the
critical role of Aire in negatively selecting autoreactive T cells (16, 28), we next sought to
determine if autoreactive CD4+ T cells specific for the BPIFB9 protein could induce ILD.
Aire−/− mice were immunized with recombinant BPIFB9 or a control protein (maltose
binding protein tag) to expand a population of antigen-specific T cells. CD4+ T cells were
isolated from lymphoid organs 10 days post-immunization and confirmed by Enzyme-linked
immunosorbent spot (Elispot) for the presence of an expanded population of antigen-specific
cells (Fig. 4B), prior to adoptive transfer (4x106 – 10x106 CD4+ T cells/recipient) into
immunodeficient mice. Recipients were analyzed 4–8 weeks post-transfer for lung
pathology. Nearly all mice receiving BPIFB9-specific cells (7/9) demonstrated CD4 T-cell
infiltrates similar to the spontaneous ILD in Aire−/− mice (Fig. 4C). Overall the disease in
BPIFB9-recipients was significantly greater than in mice receiving MBP-specific cells (Fig.
4C–D), indicating that BPIFB9-specific T cells are sufficient to cause ILD. Additionally,
because we detected BPIFB1 autoantibodies in some patients with lung fibrosis, we assessed
whether the murine autoimmune ILD seen in Aire−/− mice can evolve into other
pathological features of ILD, including interstitial pneumonia and fibrosis. Aged animals at
23 weeks and 45 weeks developed spontaneous interstitial pneumonia and significant
pulmonary fibrosis (Fig. 4E), particularly at 45 weeks, indicating these pathological features
of ILD can develop downstream of an autoimmune response to a lung self-antigen.
Importantly, our studies in the murine model of human APS1 ILD confirm that lung antigen-
specific T cell responses can induce ILD and recapitulate key features of lung-specific
autoimmunity seen in human subjects with ILD.
Role of thymic tolerance in ILD
We next sought to investigate whether central tolerance induction to lung proteins expressed
in the thymus has a potential role in ILD. Having previously demonstrated that thymic
BPIFB9 expression is Aire-dependent (14), we first confirmed that this expression pattern
maps specifically to medullary thymic epithelial cells (mTEC) in Aire−/− and Aire+/+ mice
given the essential function mTECs have in maintaining central immune tolerance (Fig. 5A).
In order to test whether a loss of lung-antigen expression in the thymus leads to ILD, we
performed a thymic graft experiment in mice by transplanting donor thymi from BALB/c
Aire−/− and Aire+/− newborn mice into athymic BALB/c nude mice (n=4 for each group).
Sera from recipient mice were analyzed 10 weeks post-transplant specifically for BPIFB9
autoantibodies since we demonstrated this is a marker for ILD in our model. All of the
recipients that received Aire−/− thymi developed BPIFB9 autoantibodies (mean
index=74.08) and histologic evidence of lung disease with lymphocytic infiltrates of T and
B cells (Fig. 5B–D), whereas none of the Aire+/− thymi recipients had detectable
autoantibody levels (mean index=0.1892, P=0.0286). Taken together, these results
demonstrate the importance of thymic lung antigen expression to ILD in the Aire model and
suggest a potential role that central tolerance to lung antigens such as BPIFB1 has in human
ILD pathogenesis.
Autoimmune targeting of BPIFB1 in ILD
Having established a strong link between BPIFB1 autoreactivity and human ILD, we next
sought to demonstrate that a break in tolerance to BPIFB1 could lead to autoimmune ILD.
Because BPIFB1 autoantibodies are found in non-APS1 ILD patients, we wished to test for
autoimmunity to BPIFB1 and lung disease independent of a defect in Aire. We obtained
Bpifb1−/− mice because immune cells in these animals may in theory be unable to unable to
develop self-tolerance to BPIFB1 (29). Indeed, Bpifb1−/− mice immunized with
recombinant BPIFB1 protein developed robust BPIFB1-specific B and T cell responses that
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were not seen in mice immunized with a control antigen (Figs 6A–B). Lymphocytes were
harvested from the spleens of these mice and 2.5 x107 cells were adoptively transferred into
BPIFB1-sufficient Rag2−/− animals. Mice receiving BPIFB1-specific immune cells
collected from Bpifb1−/− mice immunized with BPIFB1 protein developed lung disease
indistinguishable from the lung infiltrates in Aire−/− mice and APS1 patients, whereas mice
receiving cells from wild-type immunized littermates did not develop any disease (Fig. 6D).
Thus, inducing a break in immune tolerance to BPIFB1 allows for the generation of
BPIFB1-reactive cells that are capable of inducing lung-specific ILD and robust BPIFB1-
specific autoantibodies. Taken together, our results strongly suggest that immunoreactivity
to BPIFB1 leads to autoimmune lung disease in a subset of patients, both as a result of a
negative selection defect mediated by Aire and in other ILD settings in which a loss of self-
tolerance occurs.
Discussion
In summary, we show that autoantibodies to the lung self-antigen BPIFB1 are found in
diverse subjects with ILD and may serve as a marker of lung-specific autoimmune disease.
In our study, 100% of patients with APS1 and clinically verified ILD demonstrate BPIFB1
autoantibodies, confirming a strong correlation between ILD and our marker. By extending
these findings from APS1, a model of organ-specific autoimmunity, to patients with
systemic autoimmunity in CTD-ILD, we find that BPIFB1 is also a targeted lung antigen
outside of APS1 disease. Moreover, the presence of BPIFB1 autoantibodies in idiopathic
ILD is consistent with a marker of lung-specific autoimmunity rather than a general marker
associated with autoimmune inflammation. Our demonstration in mice that BPIFB1-specific
immune responses leads to ILD, provides substantial evidence that autoreactivity targeting
BPIFB1 is pathogenic in a subset of human ILD patients.
By translating clinical studies in humans to immunologic studies in the murine model, we
are able to demonstrate a lung-specific mechanism of disease pathogenesis. Though earlier
investigations have suggested a role for autoimmune injury in ILD pathogenesis, they have
not established a mechanistic link to lung-specific autoimmunity. For example, ILD patients
harbor autoantibodies to human lung and lymphocytes that proliferate in response to
autologous human lung extracts, and studies in limited cohorts have described
autoantibodies to annexin-1 and cytoskeletal proteins, including antigens reported in other
inflammatory disease (7–9). Given the wide tissue distribution of these putative targets, such
antigens may represent less dominant epitopes that arise during systemic inflammation (30,
31). In contrast, our lung-specific marker is significantly elevated in a subset of a large ILD
cohort without significant elevation in over 350 control subjects and the corresponding
marker tracks with disease severity in our animal model of ILD. Moving beyond disease
correlation, we show directly in our murine model how the loss of immune tolerance to a
lung self-antigen may provoke a lung-specific autoimmune response by demonstrating that a
lack of BPIFB9 expression in the thymus led to the induction of BPIFB9 autoantibodies and
lung infiltrates comprised of T and B cells. Furthermore, we found that the adoptive transfer
of lung-specific, BPIFB9-specific CD4 T cells induces ILD. Finally, in order to confirm the
pathogenicity of the BPIFB1 antigen and to evaluate the role of autoimmune targeting of
BPIFB1 in non-APS1 patients, we demonstrated that immunoreactivity to the BPIFB1 lung
antigen leads to ILD independent of a defect in Aire. Taken together, these data support the
role of a break in immune tolerance to BPIFB1 in ILD and furthermore suggests a potential
link of failed thymic tolerance to ILD pathogenesis beyond the APS1 disorder.
Several important questions are raised by the results of our study. First, we find that
antibody-positive individuals can manifest a range of lung pathology. We demonstrated in
mice that immune targeting of BPIFB1 is sufficient to cause ILD, though it remains unclear
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whether BPIFB1 is the dominant antigen in disease pathogenesis. BPIFB1 may represent
one of several lung autoantigens associated with ILD; for example, another bronchiolar
antigen, KCNRG (Potassium channel regulator), has been identified in APS1 patients (13),
and it is possible that peripheral lung proteins are also targeted as lung disease propagates.
Such a temporal pattern would be consistent with our observation in mice that the ILD is
initiated at the bronchiolar epithelium and subsequently spreads distally to cause pathologic
changes in the peripheral parenchyma (14). Moving forward, it will be important to
determine if autoreactivity to other lung antigens can likewise be mechanistically linked to
ILD and found in other subsets of ILD patients. Another question is why do we see ILD
both in combination with a range of autoimmune disorders as well as in patients with
idiopathic forms of the disease? Because our work supports a model where loss of tolerance
to one or more lung-specific autoantigens leads to lung-specific injury and autoimmunity
with resultant ILD, it is possible that different paths of tolerance breakdown progress to a
common endpoint of ILD. Patients without mutations in AIRE may have other, less severe
defects in immune tolerance that also predispose to autoimmunity and in the setting of such
tolerance defects, certain forms of lung injury or stress in the pulmonary epithelium may go
on to produce ILD (32, 33). Finally, the significance of autoantibodies in disease-free
individuals requires further study. Prospective study of samples from at-risk patients will be
important to determine if BPIFB1 autoantibodies predict development of ILD, consistent
with other autoimmune diseases where positive autoantibodies precede clinical disease (34,
35). Notably, monitoring of APS1 patients positive for BPIFB1 autoantibodies without
current lung disease (Table 1) may be revealing.
Our findings also have several other important clinical implications. First, the BPIFB1 assay
may identify ILD patients with lung-specific autoimmunity that may benefit from
immunomodulatory treatments. Second, identifying critical target antigens like BPIFB1 will
enable the study of key effector mechanisms of autoimmune damage allowing for
development of novel, targeted immunotherapies that obviate generalized
immunosuppression (36, 37). Finally, the study of BPIFB1 antigen may lead to development
of additional diagnostic tools to measure BPIFB1-specific T cells in clinical samples such as
bronchoalveolar fluid or peripheral blood (27). Such immune cells may be critical mediators
of ILD and their measurement may help predict a clinical response. The results here
combine the examination of basic tolerance mechanisms in a mouse model with insights
gained from a rare human autoimmune syndrome to allow a broader understanding of
potential targets of disease in a subset of ILD patients. Looking forward, continuing to
follow such an approach may continue to provide new insights into ILD pathogenesis,
prognosis, and ultimately its treatment.
Materials and Methods
APS1 subjects, ILD subjects and controls
All subjects in the study had informed written consent. The study protocol was reviewed and
approved by the institutional review board at UCSF and ethics committee at Uppsala
University. Sera from 27 non-ILD lung disease controls, 48 patients with connective-tissue
associated ILD and 108 patients with idiopathic ILD were obtained from the UCSF
Interstitial Lung Disease database, a longitudinal cohort study at UCSF (38). Subject
diagnosis was made based on a multidisciplinary review in the UCSF ILD clinic. Sera from
104 subjects with confirmed APS1 and control subject sera in Figure 1 comprising of 126
healthy blood donors, 51 patients with asthma and 51 patients with chronic obstructive
pulmonary disease (COPD) are from an IRB approved cohort study at Uppsala University
(12, 13). The diagnosis of APS1 was based on presence of at least 2 of 3 major clinical
components of APS1 (Addison’s disease, hypoparathyroidism, and chronic mucocutaneous
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candidiasis). The following diagnostic criteria were used: mucocutaneous candidiasis
(candidal infections in the oral mucosa, skin or nails for >3 months); hypoparathyroidism
[subnormal plasma calcium concentration (<2.15 mmol/L) and supranormal plasma
phosphate concentration together with normal or low PTH concentrations, and normal renal
function]; Addison’s disease (subnormal serum cortisol together with elevated plasma
ACTH concentrations or failure to reach s-cortisol of 550 nmol/L at 30 or 60 min of an
ACTH stimulation test) [the majority of the patients diagnosed with Addison’s disease also
displayed specific 21-hydroxylase autoantibodies; the majority of the patients were also
demonstrated to have typical mutations in the Aire gene. Other control sera shown in Figure
2 comprising 42 Type 1 diabetes subjects, 35 Type 2 diabetes subjects and 46 healthy
subjects were obtained from banked samples in an IRB approved cohort study at the UCSF
Diabetes Center.
Generation of 35S-Radiolabeled BPIFB1, BPIFB9 and IFNĮ radioligand binding
autoantibody assays (RLBA)
Full-length cDNAs for human BPIFB1 or IFNř and mouse BPIFB9 or BPIFB1 were used
as templates for in vitro transcription and translation and labeled with 35S-methionine using
the TNT system kit (Promega). Radiolabeled proteins were immunoprecipitated in duplicate
or triplicate with serum or control antibodies in 96-well PVDF filtration plates (Millipore).
In each well, 20,000 counts per minute (cpm) of 35S-proteins and 2.5Ťl serum were used for
immunoprecipitation. The radioactivity of the immunoprecipitated material was quantified
with the use of a liquid scintillation counter. For each assay, serum from an APS1 patient
with ILD and a healthy control (BPIFB1 or IFNř); serum from an Aire−/− and Aire+/+
mouse (BPIFB9); or serum from a Bpifb1+/+ and Bpifb1−/− mouse (BPIFB1) served as
positive and negative standards, respectively. The autoantibody index was calculated as
follows: [cpm in the unknown sample –cpm in the negative standard] ÷ [cpm in the positive
standard– cpm in the negative standard] x 100). RLBAs were performed in 2 independent
laboratories using the same antigen construct. The upper limit of the normal range for each
assay was defined as the mean value obtained for the healthy control patients tested in each
lab plus 4 SD. In the competition assay, the sample was pre-incubated with 2.5Ťg of BSA or
recombinant BPIFB1 protein (Abnova H00092747-P01) before running through the RLBA
as described above.
Sequential Immunoprecipitation
Recombinant 35S-radiolabeled protein (150,000 cpm) was precipitated with a commercial
anti-BPIFB1 antibody (Abnova #H00092747-B01P) as a control or 2.5Ťl of serum from
each patient. Antibody-antigen complexes were captured on protein-A Sepharose beads and
then removed by centrifugation. The remaining supernatant was subjected to a second round
of immunoprecipitation using the same serum sample. The third and final
immunoprecipitation of protein was performed with the commercial anti-BPIFB1 antibody
and the immunoprecipitate was analyzed by SDS-PAGE, followed by autoradiography. The
signal intensities were quantified using Kodak Molecular Imaging Software.
Recombinant BPIFB1 and BPIFB9 proteins
Recombinant BPIFB9 protein was generated as previously described (14). Mouse BPIFB1
protein was generated according to the same methods. The primers used for subcloning
mouse BPIFB1 into the expression vector were: forward 5̘-
TTAGGTACCAATGGCCGGCCCGTG-3̘; reverse 5̘-
TAACCTGCAGGTCACTGGGAGACAG-3̘.
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Indirect Immunofluorescence Staining
Frozen sections (8Ťm) of bovine lung tissue were fixed and blocked in PBS + 1% bovine
serum albumin + 3% serum from same species as the secondary antibody, overnight at 4°C.
Primary incubation with subject sera (1:1000) was for an hour followed by a donkey anti-
human Dylight 594 (Jackson Immunoresearch) secondary antibody (1:1000) for 20 minutes.
An anti-BPIFB1 antibody (Abnova, #H00092747-B01P) (1:50) was incubated for an hour,
followed by a goat anti-mouse Dylight 594 secondary (Jackson Immunoresearch) (1:1000)
for an hour. Images were obtained at 20X magnification on a confocal microscope (SP5,
Leica).
Immunostaining
Immune cell subtypes were visualized by immunohistochemistry using antibodies specific
for CD4 (BD Biosciences), CD3 (Dako), and B220 (SoutherBiotech) and Elite ABC reagent
followed by a DAB staining kit (Vector Laboratories) on 10-micron frozen or 5-micron
paraffin-embedded sections of lungs. Images were obtained using an AxioCam with
AxioVision software (both from Carl Zeiss MicroImaging, Inc.) at 5X and 10X objective on
a brightfield microscope (Carl Zeiss).
Mice
Aire−/− mice were generated as described (14). Bpifb1−/− mice were generated by Lexicon
Pharmaceuticals and obtained from the Mutant Mouse Regional Resource Center (Stock:
032698-UCD)(39). Rag2−/− mice used in the BPIFB1 adoptive transfer experiments were
purchased from Taconic (RAGN12). All mice were housed in a pathogen-free barrier
facility at UCSF and all procedures were approved by the UCSF Institutional Animal Care
Committee and Veterinary Services, and adhere to the NIH Guide for the Care and Use of
Laboratory Animals. Organs from mice were harvested, a portion of which was snap frozen
for frozen sectioning and the remaining tissue fixed overnight in 10% formalin, embedded in
paraffin and sectioned. The UCSF Mouse Pathology Core performed Masson’s Trichrome
and hematoxylin and eosin staining.
Immunization and adoptive transfer of immune cells and serum
Aire−/− mice were immunized subcutaneously with 200ŤL of a 1:1 mixture of complete
Freund’s adjuvant (CFA) (6mg/mL) and recombinant BPIFB9 (2mg/mL) or maltose binding
protein (MBP) and ten days post-immunization mice were sacrificed. The serum was
collected and tested in the BPIFB9 RLBA to assess for BPIFB9 autoantibodies. Draining
lymph nodes and spleens were harvested and CD4 cells were isolated by negative selection
using magnetic bead separation (Stemcell technologies). 4–10x106 cells per mouse were
transferred into immunodeficient mice by retro-orbital injection. Mice were sacrificed 4–8
weeks post-immunization, and lungs were infused with OCT and snap frozen for analysis.
Fifty microliters of serum from BPIFB9-immunized mice or wild-type controls was injected
every other day for a period of 10 days into wild-type mice and 7 days later the mice were
sacrificed and lungs analyzed for histological evidence of disease. Bpifb1−/− mice were
immunized intraperitoneally with 200ŤL of a 1:1 mixture of CFA (6mg/mL) and
recombinant BPIFB1 (2mg/mL) followed by weekly subcutaneous immunizations for 3
additional weeks with recombinant protein mixed in incomplete Freund’s adjuvant. Mice
were bled weekly to check for BPIFB1 autoantibodies and once sacrificed 2.5 x107
splenocytes were adoptively transferred into RAG2−/− mice.
Thymic transplantation
Thymi were removed from 1–2 day old BALB/c Aire−/− or Aire+/− animals and placed into
culture in DMEM media supplemented with 100 U/ml penicillin, 100 mcg/ml streptomycin,
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2 mM glutamine, 10% FCS, and 1.35 mM 2-deoxyguanosine (Sigma-Aldrich) for 7 days to
deplete bone marrow-derived cells. The thymi were washed in DMEM media without 2-
deoxyguanosine for 2 h and transplanted under the kidney capsule of adult nude mice on the
BALB/c background. Ten weeks after transplantation, the serum was analyzed for BPIFB9
autoantibody titer and paraffin-embedded lungs analyzed for tissue infiltration of T (CD3)
and B (B220) cells as described above.
Elispot
In brief, plates (Millipore) were coated with 2 Ťg/ml of anti–mouse IFN ś mAb (BD
Biosciences) and incubated overnight at 4°C. After blocking plates with complete media,
1x106 cells from lymphoid organs of immunized mice were plated in triplicate into wells
containing media and 10Ťg/mL of recombinant BPIFB9, BPIFB1, ova peptide or ovalbumin
protein. The plates were incubated for 36 hrs. at 37°C. At the completion of the incubation,
the plates were washed thoroughly with PBS before adding 2 Ťg/ml of biotin-labeled IFN ś
mAb (2 Ťg/ml; BD Biosciences) and incubating for 2 hrs. at 4°C. After further incubation
with avidin–horseradish peroxidase (1:100 dilutions; BD Biosciences) for 1 h at room
temperature, the plates were developed using substrate solution (BD Biosciences) and
counted.
RNA isolation and quantitative PCR (qPCR) analysis
Total human RNAs were commercially purchased (Ambion and BioChain Institute). One
microgram of total RNA was reverse transcribed into cDNA using Superscript III reverse
transcriptase (Invitrogen). QPCR was performed with human BPIFB1 (assay ID
Hs00264197_m1) and GAPDH (assay ID Hs03929097_g1) Taqman gene expression assays
(Applied Biosystems). BPIFB1 transcript was quantified using tracheal levels as a standard
and normalized to GAPDH transcript levels in each sample. The thermal cycles of the ABI
Prism 7500 Sequence Detection System (Applied Biosystems) were 95°C for 20 seconds
followed by 45 cycles of 95°C for 3 seconds and 60°C for 30 seconds.
For mouse mTEC gene expression analysis, stromal cells from thymi of 5-week-old BALB/c
Aire−/− or Aire+/+ mice (n=5 for each) were isolated as previously described (19) and sorted
on BD FACSAria III cytometers to obtain mTEC cells (DAPI− CD45− EpCAM+ Ly51−
CD11c−). Total RNA from sorted mTEC cells was isolated (RNeasy Plus Microprep,
QIAGEN) for cDNA synthesis (SuperScript III reverse transcriptase, Invitrogen) using oligo
dT primers. QPCR for mouse BPIFB9 (assay ID #Mm00723516_m1) and GAD67 (assay ID
Mm04207422_g1) were conducted as above. Expression was normalized to beta-actin
(4352933E, Applied Biosystems) and quantified using a relative standard curve based on
lung and thymus tissue levels.
Statistics
P values for significance are indicated in the Figure legends and were all calculated with
Prism software (GraphPad V5.0) using unpaired t-tests (Mann Whitney) with a two-tailed
95% confidence interval. Receiver operating characteristics analyses and area under the
curve calculations were also performed with Prism software.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. APS1 patients with ILD harbor autoantibodies to BPIFB1
APS1 patients were screened for BPIFB1 autoantibodies by testing serum in a radioligand-
binding assay (RLBA). Ten APS1 patients had elevated BPIFB1 autoantibody titers. Six
patients (numbered in blue) had pulmonary disease confirmed in PFTs or radiographs (Table
1). Sera from healthy subjects and patients with COPD and asthma were run as controls. The
dotted line denotes the upper limit of the normal range, defined as the average value of the
healthy subjects shown + 4SD.
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Fig. 2. Patients with non-APS1 ILD harbor autoantibodies to BPIFB1
Patients were screened for BPIFB1 autoantibodies by RLBA. Seven patients with
connective tissue disease-associated ILD (CTD-ILD) and thirteen idiopathic ILD patients
had elevated BPIFB1 autoantibody titers (Tables 2–3). Sera from healthy subjects (n=46)
and patients with Type 1 (n=42) and Type 2 (n= 35) diabetics and non-ILD lung disease
(n=27) were run as controls. The dotted line denotes the upper limit of the normal range,
defined as the average value of the healthy subjects shown + 4SD.
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Fig. 3. Validation of the BPIFB1 radioligand binding assay
(A) Indirect immunofluorescence staining of frozen lung sections. Stainings (from left to
right) are shown for a serum sample from a healthy control; commercial BPIFB1 antibody;
an APS1 patient with ILD and BPIFB1 autoantibodies; and a non-APS1 ILD patient with
BPIFB1 autoantibodies. Scale bar = 150ŤM (B) A competition assay to confirm the
specificity of the bronchiolar staining pattern for BPIFB1 was performed by pre-incubating
serum samples with an equivalent amount of commercial recombinant BPIFB1 protein or
bovine serum albumin (BSA) and tested in the BPIFB1 RLBA. Representative results from
2 independent experiments. (C) A sequential immunoprecipitation was performed by taking
radiolabeled BPIFB1 protein and immunoprecipitating twice with serum from subjects with
(lanes 6–10) and without (lanes 1–3) BPIFB1 autoantibodies or a commercial BPIFB1
antibody (lane 4). A final immunoprecipitation was performed using a commercial BPIFB1
antibody and the remaining protein was run out on an agarose gel that was exposed to film.
The signal intensities of the bands were quantified using Kodak Molecular Imaging
Software and graphed as shown. At far left are 2 columns indicating the mean ± SD of the
BPIFB1 positive and BPIFB1 negative subjects. *P=0.036.
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Fig. 4. Autoimmunity to BPIFB9 induces interstitial pneumonia and pulmonary fibrosis in
Aire−/− mice
(A) Aire−/− (n=36) and wild-type mice (n=19) were analyzed for BPIFB9 autoantibody titer
by RLBA and histologic lung disease score (0–3). Shown is the score of individual mice and
the mean score ± SD for each group. The bars indicate statistically significant differences
*P=0.0001 (WT vs. 3), P=0.0002 (0 vs. 3), P=0.0185 (1 vs. 3). (B) Elispot analysis for
IFNś-secreting cells specific for BPIFB9 in immunized Aire−/− mice. Shown are the
cumulative results of 2 independent experiments indicating the mean number of spots+SD
for number of spots counted in each group, run in triplicate. *P=0.005. (C) Lung disease
score of recipient mice after adoptive transfer of BPIFB9-specific (n=9) or MBP-specific
(n=8) CD4+ T cells. *P=0.035 (D) Immunohistochemistry stain of CD4 T cells in lungs
harvested from recipient mice following adoptive transfer of BPIFB9-specific or MBP-
specific CD4+ T cells (E) Serial sections from aged mice sacrificed at the indicated time
points and analyzed for lung disease by H&E and Masson’s trichrome stains. Scale bar =
200ŤM.
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Fig. 5. Loss of BPIFB9 expression in Aire−/− thymi leads to BPIFB9 autoantibodies and lung
disease after thymic transplantation
(A) Expression of BPIFB9 mRNA in mTECs from Aire+/+ and Aire−/− mice (n=5 for each).
Glutamatic acid decarboxylase-67 (GAD67) is an Aire-independent tissue specific antigen
control. Results representative of 3 independent experiments. (B) RLBA results from
recipient mice 10 weeks post-thymic transplant of Aire−/− and Aire+/− grafts (n=4 for each).
*P=0.029. (C) Lung disease score of the thymic transplant recipients. **P=0.055. (D)
Representative immunostaining of lungs from thymic transplant recipients for T cells (CD3)
and B cells (B220).
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Fig. 6. Adoptive transfer of BPIFB1-specific B and T cells leads to ILD
(A) Radioligand binding assay to quantify BPIFB1-specific autoantibodies in Bpifb1−/−
mice immunized with ovalbumin or BPIFB1 protein. The arrow indicates day immunized.
(B) Elispot analysis for IFNś-secreting cells specific for BPIFB1 or ovalbumin harvested
from lymph nodes of immunized Bpifb1−/− mice shown in A. Cumulative results from 2
independent experiments. *P=0.005. (C) Lung histology scores of Rag2−/− mice after
adoptive transfer of lymphocytes harvested from wild-type (n=7) or Bpifb1−/− (n=7) mice
after immunization with BPIFB1 protein. Cumulative results from 2 independent
experiments shown. (D) Representative H&E sections of lungs from mice shown in C.
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Table 1
AIRE genotype and clinical data for APS1 patients with elevated BPIFB1 autoantibodies.
APS1 patient AIRE gene mutation APS1 criteria Clinical Data Clinical course BPFIB1 antibody status
1 62C>T/ 1096-1G>A AD1, MCC2, HP3
PFT: obstruction
Imaging : scattered ground glass opacities,
centrilobular nodules, bronchiectasis
Biopsy: diffuse lymphocytic bronchiolitis
Respiratory exacerbations with
wheezing, improvement with steroids
and mycophenolate
+
2 607C>T/769C>T AD, MCC, HP PFT: obstructionImaging: bronchiectasis
Antibiotic treatment for recurrent
pulmonary infections, respiratory
failure, death
+
3 769C>T/769C>T AD, MCC
PFT: restriction, obstruction
Imaging: organizing pneumonia, bronchiectasis
Biopsy: bronchiolitis obliterans, lymphoid aggregates
Wheezing, steroid treatment,
respiratory failure, death +
4 964del13/964del13 AD, HP, MCC
PFT: restriction, obstruction
Imaging: centrilobular nodules, bronchial wall
thickening, bronchiectasis, ground glass opacities
Biopsy: peribronchiolar inflammation
Chronic cough, antibiotic treatment for
recurrent pulmonary infections,
respiratory failure, death
+
5 964del13/964del13 AD, HP, MCC
PFT: restriction, impaired diffusion
Imaging: diffuse interstitial and ground glass opacities,
centrilobular nodules
Biopsy: lymphocytic bronchiolitis, interstitial
inflammation
Cough, dyspnea, improvement with
immunosuppression +
6 967_979del13/967_979del13 HP, MCC
PFT: obstruction
Imaging: centrilobular nodules, bronchiectasis
Biopsy: lymphocytic bronchiolitis, non-specific
interstitial pneumonia, lymphoid aggregates
Respiratory failure, intubation,
improvement with immunosuppression +
7 769C>T/769C>T/ AD, HP N/A4 N/A +
8 769C>T/769C>T AD, MCC N/A N/A +
9 769C>T/769C>T AD, HP N/A N/A +
10 769C>T/769C>T AD, HP, MCC N/A N/A +
1Addison’s disease;
2
mucocutaneous candidiasis;
3hypoparathyroidism;
4
not available.
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